Matthew Klein

Matthew Klein

Company: PTC Therapeutics

Job title: Chief Development Officer


Matthew B. Klein, MD, MS, FACS is Chief Development Officer at PTC Therapeutics, Inc. Prior to joining PTC, Dr. Klein was CEO of BioElectron Technology Corporation, a biotechnology company focused on development of redox active small molecules for mitochondrial disease and related disorders of oxidative stress. Prior to joining BioElectron, Dr. Klein was the Auth-Washington Research Foundation Chair of Restorative Burn Surgery at the University of Washington. Dr. Klein completed his undergraduate degree at the University of Pennsylvania where he graduated summa cum laude and Phi Beta Kappa, and received his MD degree with honors from Yale University.



Lessons Learned in the Development of Therapies for Mitochondrial Disease 2:15 pm

• Explore important learnings from over a decade of mitochondrial disease drug development • Discuss lessons learned including elements of clinical study design and regulatory strategy • Examine how these conversations are applicable to all therapeutic modalitiesRead more

day: Day Two

Panel Discussion: Evaluate the Current Challenges, Approaches & Opportunities in Targeting-Mitochondria for Age-related & Mitochondrial Diseases 9:55 am

• How can drug developers/research cut to the real barriers, and debate what is truly required to break through to successful treatments for mitochondrial diseases? • What’s the impact of COVID-19 and its repercussions on existing clinical trials/research?Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.